Rose Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Senate Health Committee Releases Cosmetics Reform Discussion Draft

Executive Summary

The committee's discussion draft of cosmetics reform legislation combines elements of the proposed Personal Care Products Safety Act and FDA Cosmetic Safety and Modernization Act, but most closely aligns with the former. NGOs likely will be pleased; small businesses, perhaps not so much.

Related Content

California Assembly Passes Bill For Professional Cosmetic Ingredient Disclosure
Trump's Budget Surprise: FDA Gets 13% Increase
Senate Health Committee To Move On Cosmetics; News In Brief
ICMAD Stands By House Cosmetics Bill, But May Be Ready To Negotiate
Surprise Hatch Bill Lays Middle Ground For Cosmetic Regulatory Reform
Think FDA Inspections Are Painful Now? These Could Be The Good Old Days
PCPC Hatching Proposal For CIR Role In FDA Ingredient Review
Handcrafted Cosmetics Sector Says Exemptions In Reform Bills Are Insufficient
PCPSA's 'No Harm' Standard Would Set High Bar For FDA Ingredient Review
Supplement Industry Offers Cautionary Tale For Mandatory Cosmetic GMPs





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts